Seeking Alpha

Steve Rosenman's  Instablog

Steve Rosenman
Send Message
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of... More
  • Italian OTC Fish Oil Study Has No Bearing On Vascepa Outcomes 40 comments
    May 9, 2013 3:33 PM | about stocks: AMRN, GSK, OMTH

    The erroneous coverage by various media outlets and Street.com slime-ball Adam Fuerstein attempts to relate a poorly designed Italian OTC fish oil study with outcomes for Omega-3 class Rx drugs. WRONG GUYS...

    Let me ask a question. If you had a headache and intended to use Tylenol at the 500mg effective dose, but only took 50mg, would you expect your headache to go away? Let me be more blunt, as someone from Aegis Capital notes, do you value a fake Rolex the same as a real one?

    The above sentiments should put to bed any concerns over this re-hashed Italian study relating to bottom of the barrel fish oil, but if not consider:

    • Vascepa has shown a dose dependent benefit. Mr. Fuerstein, since you clearly cannot read clinical trial data properly, if at all, that means the more you take, the better it works, both on linear indication and up vertically into other areas of cardio events, as proven in Jelis study. 1,000 mg is not 4,000 mg. I believe everyone can agree on that.
    • Next, the study did not use Vascepa. It did not even use Lovaza. Amarin has already proven through Marine and anchor, the chemical differences and method of action vs. standard OTC fish oil. It's simply not debatable if you look at the data.
    • Vascepa does not have the same side effects profile of other fish oils, including OTC. These side effects do the opposite you want for overall cholesterol management in relation to preventing cardio events.
    • The Italian study was barely fine for comparing OTC supplements at 1,000mg and common grades of fish oil; but completely irrelevant to relate to Rx for more than the reasons listed above, for one, IT DID NOT BREAK DOWN AND GO DOUBLE BLIND ON ANY ONE INDICATION, it grouped all potential events together with no segmentation on at-risk patients. Really...???try doing that in the U.S.

    What a joke... if anything, it promotes people to not use OTC and switch to Rx as soon as possible.

    Stocks: AMRN, GSK, OMTH
Back To Steve Rosenman's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (40)
Track new comments
  • adamfeuerstein
    , contributor
    Comments (304) | Send Message
     
    Feuerstein, not Fuerstein.

     

    I demand a correction!
    9 May 2013, 04:43 PM Reply Like
  • bullrunner911
    , contributor
    Comments (5) | Send Message
     
    Adam Feuerstein

     

    Your connections to Stephen D. Simpson and Larry Husten are certainly interesting that put out that articles today regarding AMRN. What are the odds that 2 people put out articles today in an attempt to discredit Amrn that have been bashing the same stocks as you have for years. In fact there is a history of re-tweeting and cross promotion regarding the articles the articles written by them and you not only about AMRN but numerous other stocks. I was wondering how long this attack will continue on AMRN. Scripts have been reported at 11768 for April which is the 3rd full month post launch. Can you tell us exactly what number of scripts you view as success. I have seen you put out articles on other companies with much smaller scripts sales and call it a blowout launch. Some things just do not add up.

     

    One more question. You claimed in an article that everyone will compete with Vascepa as generics will all come on line and manufacture it. You claim Vascepa is useless fish oil yet on the other hand claim everyone will want to get into the business. Dont make sense does it.
    9 May 2013, 08:23 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » Sorry, meant fartstain
    9 May 2013, 05:54 PM Reply Like
  • sblfe
    , contributor
    Comments (14) | Send Message
     
    Hey Adam- No NME eh? How in the world are you a biotech analyst when you don't understand THAT process? Isn't it reckless as a reporter to be so negligent as to report something that is completely false or something that you did not put the due diligence into? I am all about divergent views. I am ok w/ your view that fish oil is getting negative press and hence that market is shrinking. I may disagree w/ it but I won't publish false info or tout apples to orange comparisons for the sake of your argument. Be responsible.
    9 May 2013, 06:23 PM Reply Like
  • ottodawg
    , contributor
    Comment (1) | Send Message
     
    "Reporter", you're being very generous.
    9 May 2013, 08:24 PM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    feuerstein

     

    We are still waiting for you to defend the statements you made relative to the Bond Wells piece. Why cant you defend what you have said in the past? Are you not proud of what you have written, or do you just know as well as we do that they are lies?

     

    So thus, while I shouldnt have to dare you to defend the statements you have made, I will consider you perhaps the biggest coward who has ever written if you dont.

     

    Here is the list that I posted last time, to which you did not respond?

     

    Please explain why 10-15 pct growth week over week isn't a strong ramp.

     

    Please show exactly in the FDA regs where they could have already granted NME.

     

    Please explain why generics are a threat when there won't even be any for another 20 months and then they will raise LDL anyway.

     

    Please show us evidence of fish oil backlash, especially since basf is increasing capacity.

     

    Please feuerstein- everything you write is innuendo and rumor. Please prove to us you are not an empty suited rumor mongering basher. Please.
    9 May 2013, 07:01 PM Reply Like
  • sts66
    , contributor
    Comments (1058) | Send Message
     
    Don't hold your breath waiting for Fartstein to answer your questions, well......because he can't.......unless he makes up more lies, of course.....he's more like a drive-by shooter than someone interested in a running gun battle....because he knows he'll lose.....
    13 May 2013, 11:36 AM Reply Like
  • see punjabi
    , contributor
    Comments (351) | Send Message
     
    Come on Steve, Adam deserves some respect here in regards to his coverage about biotech stocks. No insult for this legendary analyst with his background in science. He has a BS degree in garbage science so please he deserves some respect for providing excellent coverage in regards to amarin and other stocks.
    9 May 2013, 07:18 PM Reply Like
  • ajbrzoz
    , contributor
    Comments (45) | Send Message
     
    Great info, Steve! Thanks!
    9 May 2013, 08:23 PM Reply Like
  • vinyyy23
    , contributor
    Comments (3) | Send Message
     
    Steve I been following you for awhile and I love the information you bring forth about the company, although sometimes over optimistic. This post is my favorite as I see you hit your breaking point with people spouting misinformation and calling it facts. Calling it like it is, hilarious!

     

    Adam, how many times do you have to be wrong on something before you stop providing half truths? I'd go cover other companies with less informed readers...
    9 May 2013, 08:23 PM Reply Like
  • steve.77
    , contributor
    Comment (1) | Send Message
     
    Sorry sblfe but AF isn't capable of being responsible, he's barely capable of being sub-human..... really a snake at best.
    9 May 2013, 08:24 PM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    Steve please tell me your thoughts of cc, any thing that surprises u good or bad, also what u think about cash burn of $60 million first qtr..thanks
    9 May 2013, 08:48 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » cash burn to be expected, that will go down. call had alot of upside surprise. scripts are musc higher than anticipated and revenues a bit higher than expected. this was NOT a slow launch. ceo more clear w/ anchor differentiation vs. competitors. great call
    9 May 2013, 08:58 PM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    Another great article from quoth the raven, he is almost as bad as af
    9 May 2013, 09:00 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » worse. jeffries $26, and Leerink $20 reiterated tonight after the CC by the way and noted that the scrits and revs were above their guidance.
    9 May 2013, 10:20 PM Reply Like
  • coopman98
    , contributor
    Comments (69) | Send Message
     
    Look forward in hearing your thoughts on CC and interim affect on SP
    Thanks
    9 May 2013, 10:24 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » there is a reason a former AMRN product manager with no IR experience is now head of IR...anyone guess why?
    9 May 2013, 11:32 PM Reply Like
  • pwt750
    , contributor
    Comments (66) | Send Message
     
    cos the 'investors' that really matter are product centric
    10 May 2013, 01:33 AM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    Because the company isn't giving out any info until it becomes a material fact so why need an ir guy and waste the $
    10 May 2013, 06:16 AM Reply Like
  • bravo33
    , contributor
    Comments (60) | Send Message
     
    Steve, thought I heard in Joe's CC comments near the end that he didn't want to add full time Amarin employees to SF because (my paraphrase) you don't want to have so many fixed assets if you want to be sold. The follow up question then asked about contract hires vs. full time employees. Seems that was another signal that there are other conversations going on that we're not privvy to. Did you hear that too? Comments? Thanks.
    10 May 2013, 06:19 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » No, b/c the CEO is a nice guy and is giving the him a nice title and some experience for his next job at another company.
    10 May 2013, 08:51 AM Reply Like
  • BiotechBillionair
    , contributor
    Comments (58) | Send Message
     
    Steve
    Here are the facts behind your Tylenol example:

     

    2 grams of Vascepa per day EPA Cmax = 155 mcg/ml
    4 grams of Vascepa per day EPA Cmax = 347 mcg/ml
    http://1.usa.gov/133vuDC
    page 37 Pharm. review

     

    Fish oil/Lovaza Cmax
    8 grams of Lovaza EPA Cmax = 80 mcg/ml
    http://1.usa.gov/10fxlYp
    page 8 FDA Pharm. review

     

    Statistical review for Anchor recommends 4 gram dose, it's safe to say 1 gram of fish oil is pissing in the wind with perhaps EPA levels as low as Cmax = 8 mcg/ml (estimate)

     

    43 times lower blood EPA levels than 4 gram dose of Vascepa, take into account the mixture ratio of DHA and EPA competing for the same receptors and your looking at a supplement that could be close to 100 times less efficacious than Vascepa.

     

    Williams
    10 May 2013, 06:55 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » For the record, just about every analyst came out this AM with research notes absolutely slamming AF's assertion that the Italian fish oil study had anything to do with Vascepa. That guy is such a twerp.
    10 May 2013, 08:55 AM Reply Like
  • Deep.Blue
    , contributor
    Comments (131) | Send Message
     
    where are you feuerstein, hiding has usual in your empty suit?
    10 May 2013, 10:10 AM Reply Like
  • rydad21
    , contributor
    Comments (34) | Send Message
     
    More like hunting for an empty seat at an Amarin meeting...
    11 May 2013, 02:11 AM Reply Like
  • bullrunner911
    , contributor
    Comments (5) | Send Message
     
    Adam and his article writer cohorts who have been slamming the same stocks for years are cashing paychecks right now over the .30 fall their article caused. Now they will sit silently for that next raid with who knows what nonsense they can come up with. We have seen it all from every generic will manufacture Vascepa to nobody will want this fish oil. Next they will come up with some article about a possible comet Amrn HQ.
    10 May 2013, 10:23 AM Reply Like
  • Jerryg
    , contributor
    Comments (15) | Send Message
     
    For the record, Joe Bruno (JB) handled my call to IR better than anyone I have dealt with over the years. I usually view the IR head as a worthless position seated by a monkey.

     

    With regards to the call I placed to AMRN back in late March and left a message requesting a call back. I never expected it to happen but JB called back the next day apologizing for not returning my phone call earlier. The guy spent roughly (5) minutes answering my questions in detail and using clarity. The only other time I was impressed as this event was when I called the VRTX IR dept.

     

    The tone in JB's voice told me that something good was happening at AMRN although it remains to be seen if AMRN can pull this off to the expectations of some people here.
    10 May 2013, 11:39 AM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » Not saying at all JB is not good at what he's up to, the contrary, my experience with follow-ups has been excellent. Point is, if the company wanted to raise more money from the street and stay around long - term, you'd go with an industry pro that knows the investment community. They did not do this.
    10 May 2013, 01:44 PM Reply Like
  • rml360
    , contributor
    Comments (25) | Send Message
     
    Can you comment on your remarks about making progress with the fda regarding NCE? Joe, in past c calls has been a little bit more descriptive on the subject, while this time around just said "we still don't know when we will hear from the FDA"
    Any rumors on this? I think, once decided it will force serious bidders to come forward, instead of waiting another 6 months for the Anchor.
    10 May 2013, 02:07 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » just don't want to and cannot speculate anymore on timing...has not proved a good idea in the past - but my view remains the same, NCE.
    10 May 2013, 02:58 PM Reply Like
  • hakujin
    , contributor
    Comments (130) | Send Message
     
    If you asked me last year, I'd say, 'Denial! Thank god this NCE BS is no longer an overhang and is finally behind us.', yet here we are. Still an overhand yet NCE STILL means NOTHING to the fundamentals, but a great deal to the 'traders' who use it as a pseudo catalyst and those with an agenda. The authoritarian of bioscience who frequented here as well as stocktwits but threw in the towel on the stupidity that effervesces every nook and cranny of this place from the likes of Adam, The Raven, and all the other half wits: SlowNSteady (pseudonym out of respect for privacy), said repeatedly last year that NCE was not in the cards but that it mattered not one iota w/ the patent protection and was long. This is still true, whether or not Amarin's receives the coveted (though largely meaningless at this point) New Chemical Entity designation.

     

    I primarily view Amarin now as merely a victim of rotation. Just like Apple, where the fundamentals are top pedigree; yet Tutes and HFTS have turned a short eye to pump the garbage in this 2013 to the moon gold rush; When they are done pumping the turds like Yahoo, Green Mountain, Netflix, Blackberry, and the plethora of others with ridiculous valuations that never did nor will live up to any fundamental expectation (if there is or ever was any). As it stands, plenty of $$ to wipe out in the extremely bullish put/call ratio through Jan. Henceforth, I gave up on OTM call and focus on ITM.

     

    Sigh... Will this BS ever end...
    10 May 2013, 11:41 PM Reply Like
  • bakemann
    , contributor
    Comments (33) | Send Message
     
    any update on the amended loan they were or are supposed to be voting on ? was supposed to go from 100m to 300m, any thoughts on that?
    10 May 2013, 11:40 PM Reply Like
  • Steve Rosenman
    , contributor
    Comments (785) | Send Message
     
    Author’s reply » i'll be out of pocket next 2-3 weeks everyone, try not to let fartstain (my new favorite name for AF that someone posted on one of my SA strings) get away with anything...
    11 May 2013, 09:25 AM Reply Like
  • BiotechBillionair
    , contributor
    Comments (58) | Send Message
     
    Steve
    I wish you well on your travels, when you return we'll have NCE waiting for you. The FDA hasn't come out with any new documents, nothing held back on the Marine review documents, no new MAPP's, both draft Guidances for Lovaza and Vescepa are published (this is perhaps the strongest evidence for the FDA ruling) we'll have the NCE waiting for you.

     

    Congrats Amarin on Vascepa's NCE status awarded next week!
    Vascepa, Icosapent Ethyl the prodrug of EPA is an Ethyl EPA compound, after being ingested it's metabolized by pancreatic enzymes into EPA. 4 grams of Vascepa produces 6 times the EPA blood levels of Lovaza. This 6 fold increase is also magnified by Lovaza's DHA content competing for the same receptor sites, further reducing Lovaza's efficasy compared to Vascepa.

     

    The FDA finally appears ready to rule.

     

    Williams
    11 May 2013, 03:53 PM Reply Like
  • stephenhandal
    , contributor
    Comments (187) | Send Message
     
    Williams,

     

    I sure hope you're right, but you and many others including myself have speculated multiple times when NCE was going to come and it sure hasn't come so far. Furthermore, many are assuming at this point, that we'll definitely receive NCE, yet there is still a chance we'll get NME. It's not over, till it's over.
    11 May 2013, 10:31 PM Reply Like
  • Vincent Van North
    , contributor
    Comments (2) | Send Message
     
    we will receive no lies for 2 to 3 weeks
    13 May 2013, 05:35 PM Reply Like
  • pwt750
    , contributor
    Comments (66) | Send Message
     
    bet your aware F'urinestain stuck his foot in and bit down hard this time; apparently Anchor is a lost cause per his special insights.

     

    http://bit.ly/169xVMA

     

    Have a good unwind time.
    22 May 2013, 06:17 PM Reply Like
  • golfstud
    , contributor
    Comments (54) | Send Message
     
    Steve did u see fartstains comments on anchor and his reasoning to why he thinks FDA will not approve it in December? Can u tell me your thoughts as a while back u said in a response to me that u felt anchor approval was close to a 100 percent. Thanks
    24 May 2013, 07:19 AM Reply Like
  • Bruce Roseman
    , contributor
    Comments (6) | Send Message
     
    Vascepa Reduce It outcomes trial will surprise some of AMRN biggest critics.

     

    Omega-3 fats (fish oils) did the best job at reducing death from all causes (mean reduction of 23%) and death from heart problems (mean reduction 32%), but did the worst job at lowering blood cholesterol levels.
    • Statin drugs did the best at lowering blood cholesterol and were 10 times more effective than omega-3 fats, however omega-3 fats were 44% more effective than Statin drugs in reducing cardiac related deaths and 32% more effective in reducing death from all reasons.
    Click on this link and read the full PDF.

     

    http://bit.ly/10zoQVt
    26 May 2013, 03:51 PM Reply Like
  • pwt750
    , contributor
    Comments (66) | Send Message
     
    Pfizer-Funded Study Falsely Claims Fish Oil Useless

     

    http://bit.ly/133OGUG
    29 May 2013, 04:45 PM Reply Like
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.